Physician profile
Erin E Ellison
NPI 1669710786
$2,805.92
in general payments reported to CMS, 2019-2025
32 companies · $996 in 2025
The $996 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.42 · 2022: $374 · 2023: $667 · 2024: $717 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.04 | 2021-2025 | |
| Novo Nordisk INC | $472.96 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $237.34 | 2023-2025 | |
| Astellas Pharma US INC | $162.14 | 2023-2025 | Veozah |
| Lilly USA, LLC | $143.89 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Novartis Pharmaceuticals Corporation | $138.80 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $137.33 | 2022-2025 | Rexulti |
| Amgen INC. | $117.72 | 2022-2024 | Repatha, Otezla, Prolia |
| Lundbeck LLC | $102.00 | 2023-2024 | Rexulti, Vyepti |
| Shield Therapeutics INC | $97.43 | 2022-2025 | |
| Axsome Therapeutics, INC. | $79.19 | 2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $73.36 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $71.55 | 2022-2025 | Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $70.66 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $32.14 | 2023 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.39 | 2025 | Caplyta |
| Acella Pharmaceuticals, LLC | $27.88 | 2023-2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $26.63 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $23.44 | 2025 | Fanapt |
| Corcept Therapeutics | $22.73 | 2025 | Korlym |
| Covis Pharma Gmbh | $22.60 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.53 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.71 | 2024 | Xifaxan |
| Evofem Biosciences, INC. | $18.60 | 2022 | |
| Mayne Pharma Commercial LLC | $18.42 | 2021 | |
| Mylan Specialty L.P. | $15.82 | 2022 | |
| Linus Health, INC. | $15.80 | 2023 | |
| Sunovion Pharmaceuticals INC. | $15.57 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.54 | 2024 | Voquezna |
| Azurity Pharmaceuticals, INC. | $14.39 | 2023 | Adthyza |
| Dynavax Technologies Corporation | $14.27 | 2023 | Heplisav-B |
| Supernus Pharmaceuticals, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.